Valuation
26% of the score, 33% here after data gaps
5median 56
Krystal Biotech, Inc. is valued at 53.7x its operating profit, including debt: a very rich multiple.
60x
50x
35x
25x
18x
12x
8x
53.7x
Full points at 8x or less, none from 60xfull points
KRYSKrystal Biotech, Inc.
$337.24+132% 1Y
$337.24
$137.4652 weeks$371.35
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 11 out of 100, Weak
Weak. Krystal Biotech, Inc. scores higher than 6% of the 1,794 companies Ryufin scores.
Held back by valuation and return on capital, with nothing carrying it far.
Healthcare median 28 · all companies 57
How the score has moved
At each fiscal year end, from the reports and price of the time5
6
7
0
11
2020202120222023today
The biggest move was up 11 points from 2023 to today, mostly capital allocation.
Return on capital
18% of the score, 23% here after data gaps
0median 34
Over 7 years the business earned -13% a year after tax on the capital it uses.
2%
8%
15%
25%
-13%
None at 2% or less, full points from 25%full points
7 years agolatest 42%
Return on new capital
16% of the score, 20% here after data gaps
0median 49
No operating profit over the period, so nothing was earned to reinvest.
Capital allocation
14% of the score, 18% here after data gaps
40median 64
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 9.8% a year over 5 years: new shares
05%
-3%
9.8%
0 pointsfull points
Assets against salesAssets grew 28% a year, sales 177%
10012%
-2%
-149%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Fewer than five years of margins on file.
Balance sheet
Taken out: its 8% is shared by the others
n/ano data
No debt or interest figures on file.
Earnings quality
6% of the score, 8% here after data gaps
36median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Cash against profitOperating cash flow was 0.77x profit over 3 years
150.7x
1x
1.3x
0.8x
0 pointsfull points
AccrualsProfit ran ahead of cash by 0.3% of assets
588%
0%
-8%
0.3%
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For KRYS, cycle position and balance sheet could not be measured from the filings, so they are taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
On our screens:Most shorted stocks